Identification of an 'exceptional responder' cell line to MEK1 Inhibition: Clinical implications for MEK-targeted therapy

Molecular Cancer Research

Volumn 14, Issue 2, 2016, Pages 207-215

  Gannon, Hugh S ^a,b   Kaplan, Nathan ^a,b   Tsherniak, Aviad ^a   Vazquez, Francisca ^a,b   Weir, Barbara A ^a,b   Hahn, William C ^a,b,c   Meyerson, Matthew ^a,b,c  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL FUSION PROTEIN 1; BCR ABL PROTEIN; CASPASE 9; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; REFAMETINIB; SELUMETINIB; SHORT HAIRPIN RNA; TRAMETINIB; UNCLASSIFIED DRUG; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SENSITIVITY ANALYSIS; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGY; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; LUNG NEOPLASMS; MUTATION; PROCEDURES; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958158672     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0321     Document Type: Article

References (32)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
3. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
4. Wagle N, Grabiner B, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a Phase I trial of everolimus and pazopanib. Cancer Discov 2014;4:546-53.
5. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 2014;124:1582-6.
6. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7.
7. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2014;43(D1):D805-11.
8. Cowley GS,Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 2014;1: 140035 doi: 10.1038/sdata.2014.35.
9. Shao DD, Tsherniak A, Gopal S, Weir BA, Tamayo P, Stransky N, et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 2013;23: 665-78.
10. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84-7.
11. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014;11:783-4.
12. Clark GJ, Cox AD, Graham SM, Der CJ. Biological assays for Ras transformation. Methods Enzymol 1995;255:395-412.
13. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res 2015;21: 1935-43.
14. ImielinskiM, Berger AH, Hammerman PS,Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20.
15. The Cancer Genome Atlas. 2014. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
17. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
18. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2011;44:133-9.
19. Choi YL, Soda M, Ueno T, Hamada T, Haruta H, Yamato A, et al. Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis 2012; 33:956-61.
20. Nelson DS, Van Halteren A, Quispel WT, Van Den Bos C, Bovée JV, Patel B, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015;54:361-8.
21. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H , et al.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124:3007-15.
22. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy-cell leukemia. Nat Genet 2014;46:8-10.
23. Marks JL, Gong Y, Chitale D, Golas B, Mclellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68:5524-8.
24. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139-46.
25. Infante JR, Fecher LA, FalchookGS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-81.
26. Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 2015;14:513-5.
27. Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee S-N, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 2014;13:141.
28. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 2015; 15:577-92.
29. Wagle N, Berger MF, Davis MJ, Blumenstiel B, De Felice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
30. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT). J Mol Diagn 2015;17: 251-64.
31. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014;346: 1480-6.
32. Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, et al. Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J Clin Oncol. 2015 Aug 31. [Epub ahead of print].